Clinical Trials Logo

Clinical Trial Summary

This is a randomized investigator and participant blinded, sponsor unblinded, multicenter study that evaluates the safety and efficacy of ociperlimab with tislelizumab and histology-based chemotherapy compared with treatment with tislelizumab and histology-based chemotherapy in participants with previously untreated locally advanced, unresectable, or metastatic NSCLC


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05014815
Study type Interventional
Source BeiGene
Contact
Status Active, not recruiting
Phase Phase 2
Start date November 16, 2021
Completion date October 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03987087 - A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC Phase 2
Not yet recruiting NCT04654520 - A Randomized Study of Primary Tumor Radiotherapy for Patients With Stage Ⅳ NSCLC N/A